NEW YORK (GenomeWeb) – Veracyte reported after the close of the market on Monday that its third quarter revenues rose 34 percent year over year, as its genomic testing volume rose 23 percent during the same period.

For the three months ended Sept. 30, the South San Francisco, California-based company reported Q3 revenues of $23.5 million, up from revenues of $17.5 million a year ago and beating the average analyst estimate of $21.5 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

A new study finds that a placental protein linked with preeclampsia can be targeted by RNA silencing, according to the New Scientist.

A settlement is expected in a Duke University lawsuit hinging on using falsified data to win grants, Retraction Watch and Science report.

In PNAS this week: approach for analyzing the expression of endogenous retroviruses, circular RNAs that influence host-virus interactions, and more.

A phylogenetic analysis finds that the rare hemimastigotes form their own supra-kingdom, CBC reports.